DWTX highlights Halneuron potential for chemotherapy-induced neuropathic pain
Halneuron, a selective NaV1.7 inhibitor, is positioned as a first-in-class, durable therapy for chemotherapy-induced neuropathic pain, citing durable efficacy and a strong safety profile in clinical trials.
Halneuron, a selective NaV1.7 inhibitor, targets a large unmet need in chemotherapy-induced neuropathic pain, showing durable efficacy and a strong safety profile in clinical trials.
Synthetic manufacturing ensures supply and IP protection, with phase III and NDA milestones planned.Based on Dogwood…